Union Agriculture and Farmers' Welfare Minister Shivraj Singh Chouhan will unveil the vaccine at the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD) in Bhopal.

Developed indigenously by ICAR-NIHSAD, Bhopal, the vaccine is India's first of its kind against the H5N1 HPAI virus belonging to Clade 2.3.2.1a.

Highly pathogenic avian influenza is a severe infectious disease that affects poultry. Outbreaks can cause mortality rates of nearly 100% among infected birds, resulting in substantial financial losses for poultry farmers due to large-scale culling and trade restrictions.

The impact extends beyond poultry farms, affecting international trade, poultry product prices and the livelihoods of farmers. Since the disease was first detected in India in 2006, the country has reported more than 500 combined outbreaks involving the H5N1 and H5N8 subtypes.

A major bird flu outbreak could reduce India's GDP growth by up to 1.5%, while more than 20% of the country's poultry population could be at risk if the disease spreads unchecked. The 2006 outbreak alone caused estimated direct and indirect losses of Rs 2,200-3,000 crore.

An outbreak in Manipur also resulted in economic losses equivalent to 0.5% of the state's GDP.

Beyond its economic consequences, bird flu poses a public health concern. According to the World Health Organization (WHO), 1,003 human cases of H5N1 avian influenza, including 479 deaths, have been reported across 25 countries, including India, since 2003.

Studies have identified the H5N1 strain known as Clade 2.3.2.1a as responsible for a significant proportion of bird flu outbreaks in chickens. More recently, infections involving this strain have also been detected in various animal species, including mammals, as well as in three human cases.

Controlling the spread of the virus is therefore crucial not only to minimise economic losses for poultry farmers but also to reduce the risk of transmission from birds to other animals and humans.

Currently, no specific commercial vaccine is available against the H5N1 virus belonging to Clade 2.3.2.1a. The development of an indigenous vaccine is therefore considered an important step towards strengthening India's preparedness against avian influenza.

The vaccine developed by ICAR-NIHSAD aims to address this gap by providing protection against Clade 2.3.2.1a H5N1 virus strains circulating in India.